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Let There Be Light:
Restoring Vision With Optogenetics
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There’s an old saying that
eating carrots will improve your
eyesight. Although that’s a myth—
more vitamin A can’t actually
make bad vision better—another
member of the Plantae kingdom
is being used to restore vision
in mammals. The single-celled
Chlamydomonas reinhardtii are
a species of green algae that are
phototactic, meaning they rely on
light cues to move1. They contain
a certain type of protein receptor called channelrhodopsins that
respond to specific wavelengths
of light. Although they are simple
organisms, the algae use light
cues in complex ways. They have
an area called an eyespot, where
their channelrhodopsin proteins
are clustered. When these proteins
absorb blue light, they signal
for the algae to move towards
the light source1. At a molecular
level, humans are not so different from these microorganisms.
We have similar proteins in the
photoreceptor cells of our retina,
called rhodopsins and cone opsins,
which allow us to see many different
colors, or wavelengths of light, and
we also use these light cues to
respond to our environment. But
what happens when we lose these
light-sensing proteins?
More than 1 in 3000 people
are affected by retinitis pigmentosa,
an inherited genetic disorder that
causes the death of cells in the
retina2. As the photoreceptors die,
the brain gradually loses its only
access to the visual world, and
blindness creeps in. When retinitis
pigmentosa advances throughout
the retina, the tools we normally
think of for correcting eyesight, like
glasses or Lasik surgery, become
useless—without light sensitive
cells, the brain cannot receive light
cues. Until now, that is. Scientists
are currently using a gene editing
technique called optogenetics to
harness the power of algae and
restore visual responses in humans
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who have lost the function of their
photoreceptors. Optogenetics, a
term coined by Stanford professor
and researcher Karl Diesseroth,
refers to a gene editing technique where genetic information
for light sensitive proteins, like
channelrhodopsins, is inserted into
neurons in order to control neuronal
signaling with light2. These light
sensing proteins can be inserted
into any neuron, and have opened
the door for scientists to understand and control how the brain
functions. Optogenetics is currently
being studied as a tool to help
reduce seizures, improve memory,
relieve symptoms of Parkinson’s,
understand schizophrenia, and so
much more. For people with retinitis
pigmentosa, optogenetics provides an incredible opportunity—to
experience the world though vision
again, even after photoreceptors
die.

Shedding Light on
Vision
There’s another saying that
eyes are the windows to the soul—
this time, there’s actually some
truth to the proverb. The retina is
made of layers of cells at the back
of the eyeball and has a complex,
organized architecture. If you were
to shine a light through the pupil,
you would actually see a part of the
brain, because the retina is made
of brain cells called neurons (I don’t
suggest trying this on yourself
though). The first layer of neurons
in the retina consists of the light
sensitive photoreceptor cells, which
can be divided into rods and cones.
Rods contain rhodopsins that
respond to the lowest wavelengths
of visible light, and we have 20
times more rods than we do cones3.
Objects don’t lose their color at
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night, but we see them in black in
white because we use our rods to
process in low levels of lighting.
Cones contain cone opsins, and
are sensitive to much high levels
of illumination, like in daylight
and artificial lighting4. Cones are
used for color vision, since we
have three different types of cone
opsins that respond to short (blue/
violet), medium (green), and long
(red/yellow) wavelengths of light4.
They are highly concentrated in the
fovea, a small area at the center of
the retina with high visual acuity4.
Together, rods and cones help us
see the visible spectrum of light,
from wavelengths of ~400-700
nm4.
When a photon of light
strikes a corresponding opsin in a
photoreceptor, a signaling pathway
commences through the cell to a
synapse where the photoreceptor
communicates with its neighbors,
the bipolar cells. Bipolar cells

are either depolarized (positive
charges inside cell cause an ON
signal) or hyperpolarized (negative
charges inside the cell prevent a
signal, called OFF) based on the
information they receive from the
photoreceptors3.
Next, the bipolar cells send
signals to the third layer, the retinal
ganglion cells, which project into
the brain via the optic nerve2. Each
retinal ganglion cell is sensitive
to a specific region of the visual
field, called its receptive field3.
It is easiest to think of the connections between photoreceptors
and retinal ganglion cells as a
funnel of information: multiple
photoreceptors make up a retinal
ganglion cell’s receptive field, and
talk to bipolar cells, which talk to a
retinal ganglion cell. These retinal
ganglion cells process the ON
and OFF signals, which contain
information about shape, angle,
depth, etc., and send them into the

The neuronal architecture of the retina. Modified from: OpenStax College,
Anatomy & Physiology. OpenStax CNX.
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brain along the optic nerve to the
visual cortex. In the visual cortex,
all these individual signals carrying
small pieces of information about
the world are combined into the
big picture3.

All Eyes on Opsins
As retinitis pigmentosa
progresses, the photoreceptors
are the first and primary layer
of neurons that are affected.
Since retinitis pigmentosa gene
mutations occur in the rhodopsins
of rod cells, rods degenerate and
die first, and then the disease
progresses to the cones, leading
to complete blindness5. Because
artificial lighting mimics daylight
conditions, we use color vision for
longer periods of time, meaning
we use our cones more frequently
than our rods. Unfortunately, this
also means that many patients
with retinitis pigmentosa do not
notice the onset of the disease
until the majority of their rod cells
have died, in the late stages of the
disease5. Because there are fewer
cones in the retina, gene therapies
to save the opsin proteins are often
ineffective as the population of
cells is too small to treat by the time
the disease is caught5. Unlike other
gene therapies and interventions,
by using optogenetics, scientists
are able to focus on the surviving
cells of the retina, not just the
photoreceptors. While the bipolar
cells are a candidate for intervention,
the death of photoreceptors can
often lead to remodeling of the
retina, meaning the connections
between the bipolar cells and
retinal ganglion cells may have
changed6. Therefore, retinal ganglion cells are targeted most often
in optogenetics because their
connections to the rest of brain are
the most reliable.
The history of optogenetics
has been relatively short, but very
successful. In 2006, researchers Bi
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et al. restored cellular responses to
light in mice with cell death patterns
similar to retinitis pigmentosa
using channelrhodopsins7. Though
rodents are not visually oriented
creatures, a lot of optogenetic
techniques have been tested in
mice because they have similar
neurons in their retinas and process
information in a visual cortex, just
like humans. Bi et al. showed that
after expressing channelrhodopsins
from C. Reinhardtii algae (ChR2)
in the retinal ganglion cells of
the mice, stimulation with light
successfully mimicked the ON
response in retinal ganglion cells,
and were able to trace these light
signals into the visual cortex. Since
channelrhodopsins allow positive
ions to enter a cell, the ChR2
expressing retinal ganglion cells
were able to be depolarized and
send an ON signal to the brain7.
This pathway is exactly the same as
in a normal, functioning retina, but
optogenetics allows us to bypass
the dead photoreceptors and
activate the retinal ganglion cells
directly.
To make retinal ganglion
cells express a foreign protein,
scientists take viruses carrying
genetic information for a specific
protein and introduce these viral
vectors to the retina by injecting
them into the eye with a needle.
Bi et al. (2006) used this technique,
injecting the mice retinas with
an adeno-associated viral vector (AAVV) carrying C. reinhardtii
channelrhodopsin genes7. The
safe use of AAVVs has been widely
established in animal models, and
leads to long lasting expression of
opsin proteins in retinal ganglion
cells8. In mice models, expression
of stable, functioning ChR2 proteins
was observed for up to 18 months,
an average lifespan for laboratory
mice8.
The next obvious step was
to find a way to simulate OFF
responses using optogenetics. This

Examples of light sensitive proteins commonly used in optogenetics.
Source: Rein, M. L., & Deussing, J. M. (2011). The optogenetic (r)evolution.
Molecular genetics and genomics : MGG, 287(2), 95-109

time, scientists found their answer in
a different single-celled organism.
In the oxygen-free salt lakes of
Africa, the halobacteria Natronomonas pharaonis uses yellow-light
sensitive halorhodopsins (NpHR)
to pump negative ions into their
cells9. This process hyperpolarizes
the N. pharaonis, allowing processes like respiration to occur9.
Halorhodopsins have been studied
as a potential optogenetic tool
for mimicking hyperpolarized OFF
responses. However, while ChR2s
allow positive ions to flow freely
and quickly depolarize a cell,
NpHRs are ion pumps, and only
move one negative ion at a time. A
large number of these proteins are
required in order to hyperpolarize a
cell at the same speed as ChR2s, but
when NpHRs are expressed at high
levels, cell toxicity is a common side

effect9. In 2008, a team of scientists
engineered a modified version of
N. pharaonis halorhodopsin they
called eNpHR9. This enhanced
protein could be expressed in large
quantities without harming the host
cell9.
of
So,
the
problem
mimicking OFF responses had
been solved—scientists now had
all the tools in place to make
retinal ganglion cells function, in
a simplified way, as the processing
cells for light cues. Though ChR2
and eNpHR are the most commonly
used opsins, there have been many
other types of microbial and animal
opsin proteins that have been
utilized in optogenetics, all of which
respond to certain wavelengths
of light in a different fashion,
depolarizing or hyperpolarizing a
cell. By expressing a combination
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of these proteins in the remaining
cells in the retina, scientists are
attempting to mirror the natural
firing pathway of the retinal layers
in the surviving cells of retinitis
pigmentosa patients.
These early studies were
primarily performed on mice,
which, as mentioned, are not
visually oriented animals. Since
they have similar retinal cells,
however, problems like the safety
and reliability of expressing foreign
opsins in mammals translate from
mice to humans very well. Studies
were next performed on nonhuman primates to explore how
optogenetics affects the perceptual
aspects of vision, as primates like
marmosets and macaques have
the most optical characteristics
similar to humans. Non-human
primates have a retinal architecture
composed of multiple layers of
neurons and a similar periphery
and fovea to humans10. Visual cues
are also processed along a similar
pathway into the visual cortex,
meaning non-human primates
process visual cues the same way
humans do11. Although the safe
and reliable expression of microbial
opsins in non-human primate
retinas has been established12,13 the
cognitive effects of optogenetic
intervention have been observed
by directly stimulating the visual
cortex. Surprisingly, very few
studies have studied the behavior
response of primates who have had
light sensitive proteins expressed
in their retinas.
Using AAVVs, Ju et al. 2018
expressed ChR2 in the primary
visual cortex of blind macaque
monkeys14. By implanting a blue
light laser in the cortex, they were
able to stimulate the cortical cells
while the macaques were awake and
observe their behavior. Macaques
who received the optogenetic
treatment were able to move their
eyes towards a visual cue in over
96% of the trials14. While this study
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used optogenetics to stimulate
a location in the visual pathway
upstream of the retina, the results
do suggest that inducing artificial
visual responses in primates is
possible.
And that brings us to the most
important question: if tiny proteins
from microscopic organisms can
allow blind humans to detect light,
how much vision can optogenetics
restore? What will the world look
like through modified retinas?

Many Hands Make
Light Work
To better understand this
question, we turn to other attempts
to restore vision in humans.
The field of bioelectronics has
made great strides in developing
technology to artificially create
visual sensations. The purpose of
these studies has mainly been to
restore aspects of vision useful for
daily life that give the wearer more
independence. The main types of
bioelectronic devices are retinal
implants, arrays of electrodes that
are placed directly on the retina15.
Electrical impulses are passed
through the device to stimulate
the surviving retinal cells. This
process is similar to optogenetics
in that retinal cells other than
photoreceptors are stimulated, but
is a much more invasive procedure
as the eye has to be opened and
the device permanently sits on
the retina15. With optogenetics, a
single small injection with a needle
is all that’s necessary to mimic the
effects of these devices.
Early studies of directly
stimulating the retina and visual
cortex described how recipients
of electronic implants perceived
the sensations: as phosphenes.
Phosphenes are described as
visualizing a bright spot of light,
despite the absence of a light
cue16. One individual who received

a retinal implant described these
phosphenes as, “like looking at the
night sky where you have millions of
twinkly lights that almost look like
chaos. What [he’s] in the process of
now is learning how to identify the
different constellations”17. Although
optogenetics uses light cues to
stimulate retinal ganglion cells,
because unique signaling patterns
from the photoreceptors cannot
be fully conserved, information
such as color and acuity is very difficult to replicate. Visual perception
following optogenetic therapy will
most likely be very similar to the
phosphene phenomena observed
in bioelectronic implant patients,
and it might take a very long time
to figure out how to restore color
vision in the absence of cone
opsins.
Other studies have shown
that people with microarray
implants are able to discriminate
between points of stimulation,
suggesting that what the wearer
perceives matches the patterns
of visual input, and that electronic
stimulation of the visual system can
represent accurate images of the
world18.
Many bioelectronic devices
are now being paired with a camera
to take images of the field of view,
which can then be converted into
a pattern of electrical signals and
relayed throughout the visual
system16. In this way, individuals
view the world as a collection of
repeatedly flashing phosphenes,
and must learn to interpret what
those visual cues represent. These
camera devices have become
small enough to mount on a pair of
glasses. The main success of these
devices has been allowing wearers
to discriminate between bright and
dark areas, like windows and doors.
They also help individuals notice
when people enter or exit a room,
and even identify forks and spoons
from plates on a table. So, even if
they may not be able to tell what’s
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The first image represents an electrode array that is placed on a retina. The image in the middle represents the
input a camera might capture, which is translated into a neural code and fed into the electrodes. The image on the
right illustrates the phosphenes an individual might perceive based on the pattern of electrodes.
Source: Titchener, S. A., Shivdasani, M. N., Fallon, J. B., & Petoe, M. A. (2018). Gaze Compensation as a Technique for
Improving Hand-Eye Coordination in Prosthetic Vision. Translational vision science & technology, 7(1), 2.

on the plate, people can pick up
a fork by themselves and look at
whom they’re eating with. These
descriptions of artificial vision
might not sound like anything close
to how humans process vision with
normal photoreceptors, but when
you consider that in a little over
two decades bioelectronic devices
have restored sight to the blind, it
almost sounds like a miracle.
Similar camera devices have
been suggested for pairing with
optogenetic therapy. Although
opsins like ChR2 and NpHR
can feasibly make retinal cells
sensitive to light, the threshold
for the intensity of light required
to activate this process is often
much higher than what is available
in the natural world16. Therefore,
devices to increase illumination on
the retina have been developed
to induce signals more efficiently
in the optogenetically-modified
cells. A holographic display system
mounted on goggles has been
suggested to present light cues
at a higher intensity and in a more
organized pattern16.
For the moment, we can
only make educated guesses as

to what individuals might see
following optogenetic intervention.
Their world will be black and white,
and it will take effort and practice to
interpret what a collection of light
points might represent in the real
world. However, that answer may
come much sooner than expected.
In March of 2016, a woman with
retinitis pigmentosa was the first
human to receive optogenetic
therapy19. She, along with 20
other individuals with retinitis
pigmentosa, is part of the first
human optogenetic clinical trial,
which is currently underway at the
Retinal Foundation of the Southwest
in Dallas, Texas19,20. Sponsored by a
company called Allergan, the study
is currently testing the efficacy and
longevity of expressing ChR2 in
humans, after completing safety
and maximum dosage studies in
August of 201619,20.
Another company, GenSight Biologics, started human
trials shortly after Allergan21. In May
of 2018, they began gene therapy
in 18 retinitis pigmentosa patients
using a modified ChR2 protein
that is sensitive to red light22. The
gene therapy is paired with the use

of bioelectronic visual stimulation
devices mounted on glasses, which
capture incoming signals with a
camera, convert the signals into a
neural code, and relay this code to
the treated retinal ganglion cells
through flashes of red light22. While
the Allergan study is treating fully
blind patients and is expected to
be complete in October of 2033,
the GenSight study is testing its
therapy on retinitis pigmentosa
patients with a range of limited
visual capabilities and is expected
to be complete in 202420,21. These
preliminary studies are mainly to
test the safety and effectiveness
of the treatment before it can be
offered as a medical therapy. But,
considering how quickly the field
of optogenetics has progressed,
people may be walking around
seeing the world through algae
proteins in the not so distant future.
These studies mark the first steps
towards reversing total blindness
caused by retinitis pigmentosa and
other degenerative retinal diseases.
For people who thought they may
never see again, the future looks
bright.
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